Baxalta Inc. v. Genentech, Inc., No. 19-1527 (Fed. Cir. Aug. 27, 2020)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

Baxalta Inc. sued Genentech, Inc. and Chugai Pharma- ceutical Co. Ltd.,2 alleging infringement of claims 1, 4, 17, and 19 of U.S. Patent No. 7,033,590. On December 3, 2018, the United States District Court for the District of Dela- ware iss ued a claim construction order, construing the terms “antibody” and “antibody fragment .” Following the claim construction order, the parties stipulated to non -in- fringement of the asserted claims. The district court en- tered judgment based on its claim construction order and the parties’ stipulation.